The Week Ahead: Hom...
Health Care: Drugs
Alexza Pharmaceuticals Inc. (ALXA: NASDAQ)
$4.39 -0.04 | -0.90%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 17.72M | 14.90M | 13.67M | 13.45M |
| Receivables | 0.00 | 10.00M | 0.00 | 1.41M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 23.62M | 27.55M | 42.41M | 22.13M |
| Property, Plant & Equipment, Gross | 42.40M | 45.08M | 45.05M | 41.01M |
| Accumulated Depreciation & Depletion | 25.86M | 24.65M | 20.69M | 17.41M |
| Property, Plant & Equipment, Net | 16.53M | 20.42M | 24.36M | 23.60M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 402.00K | 628.00K | 1.71M | 450.00K |
| Total Non-Current Assets | 16.93M | 21.05M | 26.07M | 24.05M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 40.55M | 48.60M | 68.48M | 46.17M |
| Accounts Payable | 2.15M | 3.60M | 2.78M | 2.70M |
| Short Term Debt | 6.46M | 12.28M | 0.00 | 2.52M |
| Other Current Liabilities | 3.50M | 12.30M | 23.90M | 16.95M |
| Total Current Liabilities | 18.72M | 34.95M | 34.38M | 25.96M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 8.06M | 12.27M | 0.00 | 15.71M |
| Other Non-Current Liabilities | 11.20M | 11.08M | 21.81M | 11.64M |
| Minority Interest | 0.00 | 0.00 | 0.00 | -13.99M |
| Total Non-Current Liabilities | 19.26M | 23.35M | 21.81M | 27.34M |
| Total Liabilities | 37.98M | 58.30M | 56.19M | 53.30M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 2.57M | -9.69M | 12.29M | -7.13M |
| Common Par | 2.00K | 7.00K | 6.00K | 5.00K |
| Additional Paid In Capital | 337.18M | 296.94M | 278.39M | 257.49M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -334.61M | -306.64M | -266.10M | -264.62M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 2.00K | -1.00K |
| Total Capitalization | 2.57M | -9.69M | 12.29M | -7.13M |
| Total Equity | 2.57M | -9.69M | 12.29M | -7.13M |
| Total Liabilities & Stock Equity | 40.55M | 48.60M | 68.48M | 46.17M |
| Total Common Shares Outstanding | 15.77M | 7.21M | 5.98M | 5.24M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 12.47M | 6.79M | 5.54M | 3.86M |
| Diluted Weighted Shares Outstanding | 12.47M | 6.79M | 5.54M | 3.86M |
| Number of Employees | 63 | 44 | 97 | 90 |
| Number of Part-Time Employees | 1 | 7 | 0 | 0 |
Portfolios with ALXA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
Latest ALXA Headlines from TheStreet
- Top Insider Trades: AEGR VVTV CCO ALXA 01.23.13 | 08:01 am
- 5 Stocks With Big Insider Buying 01.02.13 | 11:01 am
- 13 Biotech Stock Predictions for 2013 01.02.13 | 06:01 am
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- 6 Stocks On Winning Streaks Short Sellers Do Not Believe In 12.18.12 | 04:12 pm
- Stocks Socked Despite Upbeat China Numbers; Apple Falls 12.14.12 | 04:12 pm
- The Next Big Thing in Biotech: FDA Decisions
12.14.12 | 05:12 am - Alexza Pharma: Premium Selling Options Strategy 12.12.12 | 11:12 am
- Alexza Pharma: Run-Up Trade Into December's Approval Decisions 11.20.12 | 08:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
Press Releases for ALXA
- Alexza Announces Conference Call To Discuss Agreement With Teva To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Teva And Alexza Announce Teva's License To Market ADASUVE® In The U.S. - PR Newswire 05.08.13 | 08:05 am
- Alexza Pharmaceuticals To Present At Antiepileptic Drug And Device Trials (AED) XII Conference Highlighting Advances In The Treatment Of Epilepsy - PR Newswire 05.06.13 | 09:05 am
- Update: Alexza To Report 2013 First Quarter Financial Results On Tuesday, May 14, 2013 - PR Newswire 05.01.13 | 07:05 pm
- Alexza To Report 2013 First Quarter Financial Results On Thursday, May 9, 2013 - PR Newswire 04.22.13 | 05:04 pm
- Peter W. Schineller Joins Alexza Pharmaceuticals As Senior Vice President And Chief Commercial Officer - PR Newswire 03.13.13 | 09:03 am
- Alexza To Report 2012 Year-End Financial Results On Tuesday, March 26, 2013 - PR Newswire 03.06.13 | 05:03 pm
- Alexza Pharmaceuticals' Corporate Presentation To Be Webcast At Three Upcoming Investor Conferences - PR Newswire 02.25.13 | 09:02 am
- Alexza Receives Marketing Authorization For ADASUVE® (Staccato® Loxapine) In The European Union - PR Newswire 02.21.13 | 09:02 am
- Alexza Pharmaceuticals Appoints J. Kevin Buchi To Its Board Of Directors - PR Newswire 01.03.13 | 09:01 am
Partner Headlines for ALXA
- BioPharma Stock Movers For Wednesday, August 29 - Seeking Alpha 08.29.12 | 09:08 am
- 5 Pharmaceutical Companies With EMA Or MHRA Catalysts This Year - Seeking Alpha 08.28.12 | 09:08 am
- Good News for Alexza Pharma - Analyst Blog - NASDAQ 08.23.12 | 02:08 pm
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.20.12 | 09:07 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 07.18.12 | 09:07 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 07.16.12 | 09:07 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.10.12 | 09:07 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 07.05.12 | 09:07 am
- Healthcare Insights: J&J Defends, Investors Rattle Repligen, Arena Anxiety Building - Wall St. Cheat Sheet 06.25.12 | 10:06 am
- Morning Market Movers - Benzinga 06.25.12 | 09:06 am
